• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1988年《临床实验室改进修正案》的回顾与分析:合规计划与执法政策

A review and analysis of the clinical laboratory improvement amendment of 1988: compliance plans and enforcement policy.

作者信息

Rivers Patrick A, Dobalian Aram, Germinario Francesco A

机构信息

Health Management Program, College of Applied Sciences and Arts, Southern Illinois University, Carbondale, USA.

出版信息

Health Care Manage Rev. 2005 Apr-Jun;30(2):93-102. doi: 10.1097/00004010-200504000-00003.

DOI:10.1097/00004010-200504000-00003
PMID:15923911
Abstract

In 1988, Congress passed the Clinical Laboratory Improvement Amendment (CLIA), thereby extending coverage of the Clinical Laboratory Improvement Act of 1967 to include quality standards for all laboratory-based testing. The CLIA was enacted to ensure the accuracy, reliability, and timeliness of patient test results, regardless of the location where the tests were performed. This article assessed trends in the enforcement policy of the CLIA through an examination of the Laboratory Registry, an annual publication of those individuals or entities that have had sanctions imposed on them by the Centers for Medicare and Medicaid Services. We reviewed the CLIA, including its oversight, regulations that were promulgated based on it, and its enforcement procedures. We obtained the Laboratory Registries for 1993-2001. Sanctions were categorized into groups per the enforcement regulations (42 C.F.R. section sign 493.2 2000). The data indicated an increasing use of more lenient sanctions from 1997 to 2001, and a gradual increase in fraudulent activity for that same period. One possible explanation for this finding is that implementation of compliance plans by participating clinical laboratories had a mitigating effect on enforcement policy. Compliance plan guidance from the OIG provides an opportunity for laboratory service providers to be proactive in their attempts to decrease errors, and thus improve accuracy and reliability by documenting laboratory policies, procedures, and objectives.

摘要

1988年,国会通过了《临床实验室改进修正案》(CLIA),从而将1967年的《临床实验室改进法案》的覆盖范围扩大到包括所有基于实验室检测的质量标准。CLIA的颁布是为了确保患者检测结果的准确性、可靠性和及时性,无论检测是在何处进行。本文通过审查《实验室登记册》评估了CLIA的执法政策趋势,该登记册是对那些受到医疗保险和医疗补助服务中心制裁的个人或实体的年度出版物。我们审查了CLIA,包括其监督、基于它颁布的法规及其执法程序。我们获取了1993 - 2001年的《实验室登记册》。根据执法规定(42 C.F.R.§493.22000),制裁被分类。数据表明,从1997年到2001年,使用更为宽松制裁的情况有所增加,并且同期欺诈活动也逐渐增多。这一发现的一个可能解释是,参与的临床实验室实施合规计划对执法政策产生了缓解作用。监察长办公室的合规计划指南为实验室服务提供商提供了一个机会,使其能够积极主动地努力减少错误,从而通过记录实验室政策、程序和目标来提高准确性和可靠性。

相似文献

1
A review and analysis of the clinical laboratory improvement amendment of 1988: compliance plans and enforcement policy.1988年《临床实验室改进修正案》的回顾与分析:合规计划与执法政策
Health Care Manage Rev. 2005 Apr-Jun;30(2):93-102. doi: 10.1097/00004010-200504000-00003.
2
Medicare program; Medicare and laboratory certification program; enforcement procedures for laboratories--HCFA. Final rule.医疗保险计划;医疗保险与实验室认证计划;实验室执行程序——医疗保健财务管理局。最终规则。
Fed Regist. 1992 Feb 28;57(40):7218-43.
3
Medicare, Medicaid and CLIA programs; regulations implementing the Clinical Laboratory Improvement Amendments of 1988 (CLIA)--HCFA. Final rule with comment period.医疗保险、医疗补助和临床实验室改进修正案(CLIA)计划;实施1988年《临床实验室改进修正案》(CLIA)的法规——医疗保健财务管理局。附意见征求期的最终规则。
Fed Regist. 1992 Feb 28;57(40):7002-186.
4
CLIA program; simplifying CLIA regulations relating to accreditation, exemption of laboratories under a state licensure program, proficiency testing, and inspection--HCFA. Correction.临床实验室改进修正案(CLIA)计划;简化与认证、州许可计划下实验室的豁免、能力验证和检查相关的CLIA法规——医疗保健财务管理局(HCFA)。更正。
Fed Regist. 1998 Jun 15;63(114):32699.
5
CLIA program; simplifying CLIA regulations relating to accreditation, exemption of laboratories under a state licensure program, proficiency testing, and inspection--HCFA. Final rule.临床实验室改进修正案(CLIA)计划;简化与认证、州许可计划下实验室的豁免、能力验证和检查相关的CLIA法规——医疗保健财务管理局(HCFA)。最终规则。
Fed Regist. 1998 May 14;63(93):26722-38.
6
Regulatory compliance for point-of-care testing: 2009 United States perspective.即时检验的法规遵循:2009年美国视角
Clin Lab Med. 2009 Sep;29(3):463-78. doi: 10.1016/j.cll.2009.06.012.
7
Medicare, Medicaid and CLIA programs; revision of the laboratory regulations for the Medicare, Medicaid, and Clinical Laboratories Improvement Act of 1967 programs--HCFA. Final rule with comment period.医疗保险、医疗补助和临床实验室改进修正案(CLIA)计划;修订1967年《医疗保险、医疗补助和临床实验室改进法案》计划的实验室法规——医疗保健财务管理局(HCFA)。附意见征求期的最终规则。
Fed Regist. 1990 Mar 14;55(50):9538-610.
8
CLIA program; approval of the College of American Pathologists--HCFA. Notice.临床实验室改进修正案计划;美国病理学家学会的批准——医疗保健财务管理局。通知。
Fed Regist. 1995 Feb 9;60(27):7774-80.
9
Clinical Laboratory Improvement Act program fee collection--HCFA. Final rule with comment.《临床实验室改进法案》项目费用收取——医疗保健财务管理局。带评论的最终规则。
Fed Regist. 1992 Feb 28;57(40):7188-218.
10
Clinical laboratory performance on proficiency testing samples--United States, 1994.1994年美国临床实验室对能力验证样本的检测表现
MMWR Morb Mortal Wkly Rep. 1996 Mar 8;45(9):193-6.

引用本文的文献

1
Monitoring and Root Cause Analysis of Clinical Biochemistry Turnaround Time at a Tertiary Care Institute.某三级医疗机构临床生化检验周转时间的监测与根本原因分析
Cureus. 2023 Jun 1;15(6):e39821. doi: 10.7759/cureus.39821. eCollection 2023 Jun.
2
Measuring serum sodium levels using blood gas analyzer and auto analyzer in heart and lung disease patients: A cross-sectional study.使用血气分析仪和自动分析仪测定心肺疾病患者的血清钠水平:一项横断面研究。
Ann Med Surg (Lond). 2022 May 13;78:103713. doi: 10.1016/j.amsu.2022.103713. eCollection 2022 Jun.
3
Additive and Interactive Genetically Contextual Effects of HbA1c on cg19693031 Methylation in Type 2 Diabetes.
HbA1c 对 2 型糖尿病患者 cg19693031 甲基化的相加和交互遗传影响。
Genes (Basel). 2022 Apr 13;13(4):683. doi: 10.3390/genes13040683.
4
Interventions to reduce corruption in the health sector.减少卫生部门腐败现象的干预措施。
Cochrane Database Syst Rev. 2016 Aug 16;2016(8):CD008856. doi: 10.1002/14651858.CD008856.pub2.
5
Clinical implementation of RNA signatures for pharmacogenomic decision-making.用于药物基因组学决策的RNA特征的临床应用
Pharmgenomics Pers Med. 2011;4:95-107. doi: 10.2147/PGPM.S14888. Epub 2011 Sep 8.
6
No evidence of the effect of the interventions to combat health care fraud and abuse: a systematic review of literature.无对抗医疗保健欺诈和滥用的干预措施效果的证据:文献系统评价。
PLoS One. 2012;7(8):e41988. doi: 10.1371/journal.pone.0041988. Epub 2012 Aug 24.
7
Analysis of factors influencing the generation of unqualified clinical samples and measures to prevent this generation.分析影响不合格临床标本产生的因素及预防措施。
Ann Lab Med. 2012 May;32(3):216-9. doi: 10.3343/alm.2012.32.3.216. Epub 2012 Apr 18.
8
You never call, you never write: why return of 'omic' results to research participants is both a good idea and a moral imperative.你从不打电话,也从不写信:为什么向研究参与者反馈“组学”结果既是个好主意,也是一项道德义务。
Per Med. 2011 Nov;8(6):651-657. doi: 10.2217/pme.11.62.
9
Genetic testing in psychiatry: a review of attitudes and beliefs.精神病学中的基因检测:态度和信念的综述。
Psychiatry. 2011 Winter;74(4):315-31. doi: 10.1521/psyc.2011.74.4.315.
10
Impact of gene patents and licensing practices on access to genetic testing for long QT syndrome.基因专利和授权实践对长 QT 综合征基因检测可及性的影响。
Genet Med. 2010 Apr;12(4 Suppl):S111-54. doi: 10.1097/GIM.0b013e3181d68293.